



PRECISION* TRIAL : MRI to help diagnose prostate cancer

POPULATION : 500 patients / 23 centers (6 KOELIS)
Mean Age : 64 Median PSA: 6.7 Abnormal DRE²: 15%

CANCER DETECTION RATE


TRUS Random Biopsy No MRI
 TRUS Random Biopsy (10/12 cores)

MRI Targeted Biopsy MRI + Targeted biopsy (4 cores)
 MRI Negative : No Biopsy



Significant Cancer

Insignificant Cancer



MRI BEFORE BIOPSY

MRI TARGETED BIOPSY

INFORMED DECISION-MAKING

MRI - = 28% Go on Surveillance
MRI += 72% Go on Targeted Biopsy
28% Unnecessary Biopsy Avoided

HIGH PRECISION

46% more detection of significant cancer
56% less detection of insignificant cancer
3 times less biopsy cores
 Less complications & side effects

KOELIS SOLUTION ALLOWS

MRI TARGETED BIOPSY

3D PROSTATE MAPPING

QUANTITATIVE DIAGNOSIS

PERSONALIZED PATIENT CARE



*PRostate Evaluation for Clinically Important disease: Sampling using Image-guidance Or Not?

University College Hospital London and University College London

First author: Veeru Kasivisvanathan, University College, London

Study Chair: Caroline Moore MD FRCS and Mark Emberton,